METMab is a humanized monovalent antibody with neutralizing activity against MET, which, administered in association with EGFR inhibitors to patients affected by NSCLC, has significantly increased the “progression-free survival” period of patients that expressed high levels of MET (Spigel, 2011). Here, MET is linked to non-small cell lung carcinoma.